東和薬品の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2025/02/07 | 2,902 | 2,924 | 2,883 | 2,909 | -10 | -0.3% | 61,900 |
2025/02/06 | 2,926 | 2,942 | 2,893 | 2,919 | +29 | +1% | 80,200 |
2025/02/05 | 2,905 | 2,917 | 2,865 | 2,890 | -15 | -0.5% | 107,500 |
2025/02/04 | 2,940 | 2,950 | 2,894 | 2,905 | -10 | -0.3% | 106,600 |
2025/02/03 | 2,984 | 2,984 | 2,910 | 2,915 | -100 | -3.3% | 154,300 |
2025/01/31 | 3,040 | 3,040 | 3,005 | 3,015 | -40 | -1.3% | 57,600 |
2025/01/30 | 3,045 | 3,080 | 3,040 | 3,055 | +25 | +0.8% | 88,900 |
2025/01/29 | 3,070 | 3,080 | 3,030 | 3,030 | -30 | -1% | 59,500 |
2025/01/28 | 3,055 | 3,080 | 3,045 | 3,060 | -10 | -0.3% | 54,500 |
2025/01/27 | 3,070 | 3,080 | 3,050 | 3,070 | +20 | +0.7% | 75,700 |
2025/01/24 | 3,060 | 3,100 | 3,040 | 3,050 | +15 | +0.5% | 98,800 |
2025/01/23 | 3,000 | 3,050 | 2,973 | 3,035 | ±0 | ±0% | 121,900 |
2025/01/22 | 3,065 | 3,065 | 3,015 | 3,035 | -20 | -0.7% | 97,200 |
2025/01/21 | 3,120 | 3,130 | 3,040 | 3,055 | -15 | -0.5% | 74,300 |
2025/01/20 | 3,110 | 3,115 | 3,065 | 3,070 | -45 | -1.4% | 92,000 |
2025/01/17 | 3,150 | 3,155 | 3,105 | 3,115 | -35 | -1.1% | 65,500 |
2025/01/16 | 3,220 | 3,220 | 3,135 | 3,150 | -70 | -2.2% | 108,200 |
2025/01/15 | 3,255 | 3,280 | 3,195 | 3,220 | -60 | -1.8% | 99,100 |
2025/01/14 | 3,310 | 3,350 | 3,245 | 3,280 | -20 | -0.6% | 92,800 |
2025/01/10 | 3,330 | 3,390 | 3,300 | 3,300 | -50 | -1.5% | 95,100 |
2025/01/09 | 3,245 | 3,360 | 3,245 | 3,350 | +120 | +3.7% | 158,300 |
2025/01/08 | 3,315 | 3,335 | 3,220 | 3,230 | -90 | -2.7% | 116,600 |
2025/01/07 | 3,320 | 3,335 | 3,275 | 3,320 | ±0 | ±0% | 114,700 |
2025/01/06 | 3,390 | 3,395 | 3,280 | 3,320 | -35 | -1% | 126,300 |
2024/12/30 | 3,350 | 3,365 | 3,300 | 3,355 | +25 | +0.8% | 132,800 |
2024/12/27 | 3,250 | 3,330 | 3,240 | 3,330 | +75 | +2.3% | 146,700 |
2024/12/26 | 3,240 | 3,255 | 3,175 | 3,255 | +5 | +0.2% | 109,500 |
2024/12/25 | 3,245 | 3,285 | 3,190 | 3,250 | +30 | +0.9% | 215,500 |
2024/12/24 | 3,100 | 3,255 | 3,060 | 3,220 | +150 | +4.9% | 259,200 |
2024/12/23 | 2,954 | 3,070 | 2,954 | 3,070 | +155 | +5.3% | 195,100 |
2024/12/20 | 2,821 | 2,939 | 2,820 | 2,915 | +115 | +4.1% | 235,500 |
2024/12/19 | 2,790 | 2,878 | 2,790 | 2,800 | +55 | +2% | 201,800 |
2024/12/18 | 2,783 | 2,800 | 2,740 | 2,745 | -11 | -0.4% | 81,500 |
2024/12/17 | 2,773 | 2,792 | 2,738 | 2,756 | -21 | -0.8% | 83,300 |
2024/12/16 | 2,788 | 2,798 | 2,777 | 2,777 | -11 | -0.4% | 50,600 |
2024/12/13 | 2,773 | 2,829 | 2,771 | 2,788 | -20 | -0.7% | 65,600 |
2024/12/12 | 2,817 | 2,833 | 2,801 | 2,808 | -9 | -0.3% | 47,900 |
2024/12/11 | 2,835 | 2,850 | 2,802 | 2,817 | -15 | -0.5% | 55,200 |
2024/12/10 | 2,856 | 2,857 | 2,823 | 2,832 | +8 | +0.3% | 59,500 |
2024/12/09 | 2,822 | 2,853 | 2,820 | 2,824 | +5 | +0.2% | 79,000 |
2024/12/06 | 2,872 | 2,872 | 2,819 | 2,819 | -40 | -1.4% | 44,300 |
2024/12/05 | 2,882 | 2,906 | 2,835 | 2,859 | -24 | -0.8% | 110,900 |
2024/12/04 | 2,875 | 2,896 | 2,851 | 2,883 | -17 | -0.6% | 80,600 |
2024/12/03 | 2,797 | 2,914 | 2,792 | 2,900 | +103 | +3.7% | 144,500 |
2024/12/02 | 2,802 | 2,815 | 2,781 | 2,797 | -15 | -0.5% | 86,800 |
2024/11/29 | 2,798 | 2,822 | 2,780 | 2,812 | +14 | +0.5% | 91,400 |
2024/11/28 | 2,775 | 2,798 | 2,755 | 2,798 | +28 | +1% | 92,600 |
2024/11/27 | 2,768 | 2,782 | 2,736 | 2,770 | +2 | +0.1% | 120,600 |
2024/11/26 | 2,794 | 2,811 | 2,750 | 2,768 | -32 | -1.1% | 125,000 |
2024/11/25 | 2,841 | 2,856 | 2,800 | 2,800 | -20 | -0.7% | 102,600 |
101~
150
件表示中 / 6989件
類似銘柄と比較する
現在ご覧いただいている「東和薬品」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
東和薬品 | 297,600円 | +7.9% | -3.3% | 2.69% | 8.28倍 | 0.85倍 |
|
後発医薬品メーカーで国内2強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
科研薬 | 376,800円 | -6.4% | -71.8% | 5.04% | 42.09倍 | 0.94倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
ジーエヌアイ | 308,500円 | +21.7% | +999.9% | 0.00% | 12.93倍 | 4.28倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
サンバイオ | 211,900円 | - | - | 0.00% | - | 98.15倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
ゼリア新薬 | 203,800円 | +3.1% | -6.5% | 2.36% | 9.46倍 | 1.00倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム